Abstract:In the tumor milieu of head and neck squamous cell carcinoma (HNSCC), distinct B cell subpopulations are present, which exert either pro- or anti-tumor activities. Multiple factors, including hypoxia, cytokines, interactions with tumor cells, and other immune infiltrating lymphocytes (TILs), alter the equilibrium between the dual roles of B cells leading to cancerogenesis. Certain B cell subsets in the tumor microenvironment (TME) exhibit immunosuppressive function. These cells are known as regulatory B (Breg) cells. Breg cells suppress immune responses by secreting a series of immunosuppressive cytokines, including IL-10, IL-35, TGF-β, granzyme B, and adenosine or dampen effector TILs by intercellular contacts. Multiple Breg phenotypes have been discovered in human and mouse cancer models. However, when compartmentalized within a tertiary lymphoid structure (TLS), B cells predominantly play anti-tumor effects. A mature TLS contains a CD20+ B cell zone with several important types of B cells, including germinal-center like B cells, antibody-secreting plasma cells, and memory B cells. They kill tumor cells via antibody-dependent cytotoxicity and phagocytosis, and local complement activation effects. TLSs are also privileged sites for local T and B cell coordination and activation. Nonetheless, in some cases, TLSs may serve as a niche for hidden tumor cells and indicate a bad prognosis. Thus, TIL-B cells exhibit bidirectional immune-modulatory activity and are responsive to a variety of immunotherapies. In this review, we discuss the functional distinctions between immunosuppressive Breg cells and immunogenic effector B cells that mature within TLSs with the focus on tumors of HNSCC patients. Additionally, we review contemporary immunotherapies that aim to target TIL-B cells. For the development of innovative therapeutic approaches to complement T-cell-based immunotherapy, a full understanding of either effector B cells or Breg cells is necessary.

Implications for Cancer Immunology and Therapy

The Dual Role of B Cells in the Tumor Microenvironment: Implications for Cancer Immunology and Therapy

Tumor-infiltrating B cells: Their dual mechanistic roles in the tumor microenvironment

Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

B Cell Heterogeneity, Plasticity, and Functional Diversity in Cancer Microenvironments

B cells present a double-sided effect in digestive system tumors: a review for tumor microenvironment

Immune Cells Within the Tumor Microenvironment: Biological Functions and Roles in Cancer Immunotherapy

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Role of tumor microenvironment in cancer progression and therapeutic strategy

Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment

Single-Cell Informatics for Tumor Microenvironment and Immunotherapy

Exploring the dual role of B cells in solid tumors: implications for head and neck squamous cell carcinoma

Yin-yang Effect of Tumor Infiltrating B Cells in Breast Cancer: from Mechanism to Immunotherapy.

A New Perspective: Exploring Future Therapeutic Strategies For Cancer By Understanding The Dual Role Of B Lymphocytes In Tumor Immunity

Tumor Immunotherapy: Mechanisms and Clinical Applications

Tumor microenvironment as a complex milieu driving cancer progression: a mini review

New horizons in tumor microenvironment biology: challenges and opportunities

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses

B Cells in Tumor Metastasis: Friend or Foe?

Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives